National Bank of Canada’s AstraZeneca AZN Stock Holding History

National Bank of Canada’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$418M	Buy	2,137,511 +1,019,479	+91%	+$197M	0.37%	51
2025 Q4	$206M	Buy	1,118,032 +558,436	+100%	+$97.9M	0.19%	99
2025 Q3	$85.9M	Buy	559,596 +429,131	+329%	+$64.9M	0.09%	197
2025 Q2	$18.3M	Buy	130,465 +64,147	+97%	+$8.99M	0.02%	581
2025 Q1	$9.74M	Sell	66,318 -22,589	-25%	-$3.27M	0.01%	723
2024 Q4	$11.7M	Buy	88,907 +9,742	+12%	+$1.36M	0.01%	720
2024 Q3	$12.3M	Buy	79,165 +27,737	+54%	+$4.48M	0.01%	617
2024 Q2	$8.01M	Sell	51,428 -53,756	-51%	-$8.09M	0.01%	620
2024 Q1	$16.2M	Sell	105,184 -150,914	-59%	-$20M	0.02%	475
2023 Q4	$35M	Sell	256,098 -145,207	-36%	-$18.9M	0.06%	294
2023 Q3	$53.4M	Sell	401,305 -5,178	-1%	-$707K	0.08%	217
2023 Q2	$53.4M	Buy	406,483 +38,832	+11%	+$5.71M	0.1%	173
2023 Q1	$51.2M	Buy	367,651 +258,226	+236%	+$34.7M	0.13%	140
2022 Q4	$14.8M	Buy	109,425 +994	+0.9%	+$125K	0.04%	330
2022 Q3	$11.8M	Sell	108,431 -2,953	-3%	-$375K	0.06%	329
2022 Q2	$14.7M	Sell	111,384 -160	-0.1%	-$21K	0.07%	310
2022 Q1	$15.2M	Sell	111,544 -54,910	-33%	-$6.58M	0.04%	359
2021 Q4	$19.4M	Buy	+166,454	New	+$19.6M	0.07%	238

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

National Bank of Canada's AZN Position: Q1 2026 in Review

National Bank of Canada increased its AstraZeneca (AZN) stake by 91% in Q1 2026, buying an estimated $197M and bringing the position to 2,137,511 shares worth $418M. The position accounts for 0.37% of the portfolio, ranked #51.

National Bank of Canada first reported a position in AZN in Q4 2021 and has held it in 18 quarters since. 1,381 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

National Bank of Canada held 2,137,511 shares of AstraZeneca worth $418M as of Q1 2026.
National Bank of Canada bought 1,019,479 AstraZeneca shares in Q1 2026, an estimated $197M.
AstraZeneca made up 0.37% of National Bank of Canada's portfolio in Q1 2026, its #51 holding.
National Bank of Canada first reported a position in AstraZeneca in Q4 2021 and has held it in 18 quarters since.
1,381 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.